Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 safety and tolerability study of IC51 Japanese encephalitis vaccine
ACTRN12605000680662Phase 3Not yet recruiting
- Sponsor
- Intercell AG
- Start
- Oct 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Intercell AG. Planned start Oct 2006; status: not yet recruiting.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on ACTRN12605000680662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000680662.